Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situationsGert Van Assche, Axel Dignass, Bernd Bokemeyer, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialSilvio Danese, Severine Vermeire, Geert D'Haens, et al.
Alimentary Pharmacology & Therapeutics|November 30, 2023
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUSTLaurent Peyrin-Biroulet, Séverine Vermeire, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|April 6, 2019
Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical TrialEugeni Domènech, Julián Panés, Joaquín Hinojosa, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
United European Gastroenterology Journal|October 13, 2025
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST StudyAxel Dignass, Fernando Magro, Ferdinando D'Amico, et al.
Scandinavian Journal of Gastroenterology|March 8, 2018
Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitisAxel Dignass, Ayesha Akbar, Daniel C Baumgart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2024
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV TrialsNuh N Rahbari, Sebastiano Biondo, Ricardo Frago, et al.
Lancet (London, England)|August 2, 2016
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trialJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Drugs|June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situationsGert Van Assche, Axel Dignass, Bernd Bokemeyer, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialSilvio Danese, Severine Vermeire, Geert D'Haens, et al.
Alimentary Pharmacology & Therapeutics|November 30, 2023
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUSTLaurent Peyrin-Biroulet, Séverine Vermeire, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|April 6, 2019
Corrigendum: Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical TrialEugeni Domènech, Julián Panés, Joaquín Hinojosa, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
United European Gastroenterology Journal|October 13, 2025
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST StudyAxel Dignass, Fernando Magro, Ferdinando D'Amico, et al.
Scandinavian Journal of Gastroenterology|March 8, 2018
Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitisAxel Dignass, Ayesha Akbar, Daniel C Baumgart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2024
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV TrialsNuh N Rahbari, Sebastiano Biondo, Ricardo Frago, et al.
Lancet (London, England)|August 2, 2016
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trialJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Drugs|June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Pageof 18